{"id":251434,"date":"2021-10-11T00:00:00","date_gmt":"2021-10-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0127-biopharma-pemphigus-vulgaris-epidemiology-asia-pacific\/"},"modified":"2026-05-03T11:21:18","modified_gmt":"2026-05-03T11:21:18","slug":"epidim0127-biopharma-pemphigus-vulgaris-epidemiology-asia-pacific","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0127-biopharma-pemphigus-vulgaris-epidemiology-asia-pacific\/","title":{"rendered":"Pemphigus Vulgaris &#8211; Epidemiology &#8211; Asia-Pacific"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of <abbr title=\"pemphigus vulgaris\">PV<\/abbr> comprises epidemiological estimates of key patient populations in the major Asia-Pacific pharmaceutical markets (Australia, Hong Kong, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand, and Vietnam). We report both the diagnosed incidence and prevalence of <abbr title=\"pemphigus vulgaris\">PV<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Clarivate Epidemiology\u2019s forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How many people in each of the major Asia-Pacific pharmaceutical markets have been formally diagnosed with <abbr title=\"pemphigus vulgaris\">PV<\/abbr>; how many are newly diagnosed each year?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"pemphigus vulgaris\">PV<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts three patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases.<\/li>\n<li>Diagnosed prevalent cases.<\/li>\n<li>Diagnosed incident cases by severity.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251434","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251434\/revisions"}],"predecessor-version":[{"id":283870,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251434\/revisions\/283870"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}